United Therapeutics (UTHR) CFO exercises 21,000 options and sells stock

Rhea-AI Filing Summary

United Therapeutics Corporation reported insider activity by its CFO and Treasurer involving stock options and common shares. On 12/08/2025, the officer exercised a stock option for 21,000 shares of common stock at an exercise price of $146.03 per share, increasing direct holdings before sales.

That same day, the officer sold United Therapeutics common stock in a series of open-market transactions coded as sales, with weighted average prices reported from about $475.08 to $486.71 per share, executed in multiple trades at price ranges disclosed in the notes. After these transactions, the officer directly owned 8,142 shares of common stock. The filing states that the option exercise and subsequent share sales were made under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 5, 2025.

Insider Trade Summary

Net Seller: 21,000 shares ($10,050,597)

Net Sell 14 txns

Insider EDGEMOND JAMES

Role CFO AND TREASURER

Sold 21,000 shs ($10.05M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	21,000	$0.00	--
Exercise	Common Stock	21,000	$146.03	$3.07M
Sale	Common Stock	400	$475.0848	$190K
Sale	Common Stock	2,957	$476.1738	$1.41M
Sale	Common Stock	6,529	$477.1791	$3.12M
Sale	Common Stock	3,295	$477.9687	$1.57M
Sale	Common Stock	3,139	$479.157	$1.50M
Sale	Common Stock	1,559	$480.0313	$748K
Sale	Common Stock	477	$481.2245	$230K
Sale	Common Stock	523	$482.2161	$252K
Sale	Common Stock	742	$483.2864	$359K
Sale	Common Stock	739	$484.5095	$358K
Sale	Common Stock	120	$484.8467	$58K
Sale	Common Stock	520	$486.7108	$253K

Holdings After Transaction: Stock Option — 3,517 shares (Direct); Common Stock — 29,142 shares (Direct)

Footnotes (1)

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. This transaction was executed in multiple trades at prices ranging from $474.57 to $475.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $475.60 to $476.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $476.60 to $477.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $477.60 to $478.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $478.63 to $479.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $479.65 to $480.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $480.68 to $481.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $481.70 to $482.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $482.76 to $483.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $483.76 to $484.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $484.83 to $484.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $486.68 to $486.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/08/2025		M(1)		21,000	A	$146.03	29,142	D
Common Stock	12/08/2025		S(1)		400	D	$475.0848(2)	28,742	D
Common Stock	12/08/2025		S(1)		2,957	D	$476.1738(3)	25,785	D
Common Stock	12/08/2025		S(1)		6,529	D	$477.1791(4)	19,256	D
Common Stock	12/08/2025		S(1)		3,295	D	$477.9687(5)	15,961	D
Common Stock	12/08/2025		S(1)		3,139	D	$479.157(6)	12,822	D
Common Stock	12/08/2025		S(1)		1,559	D	$480.0313(7)	11,263	D
Common Stock	12/08/2025		S(1)		477	D	$481.2245(8)	10,786	D
Common Stock	12/08/2025		S(1)		523	D	$482.2161(9)	10,263	D
Common Stock	12/08/2025		S(1)		742	D	$483.2864(10)	9,521	D
Common Stock	12/08/2025		S(1)		739	D	$484.5095(11)	8,782	D
Common Stock	12/08/2025		S(1)		120	D	$484.8467(12)	8,662	D
Common Stock	12/08/2025		S(1)		520	D	$486.7108(13)	8,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$146.03	12/08/2025		M(1)			21,000	03/15/2020	03/15/2027	Common Stock	21,000	$0.00	3,517	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $474.57 to $475.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $475.60 to $476.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $476.60 to $477.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $477.60 to $478.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $478.63 to $479.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $479.65 to $480.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $480.68 to $481.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $481.70 to $482.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $482.76 to $483.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $483.76 to $484.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $484.83 to $484.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $486.68 to $486.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did United Therapeutics (UTHR) disclose in this Form 4?

The company disclosed that its CFO and Treasurer exercised a stock option for 21,000 shares of United Therapeutics common stock at an exercise price of $146.03 per share on 12/08/2025, followed by multiple open-market sales of common stock the same day.

How many United Therapeutics (UTHR) shares did the officer sell and at what prices?

On 12/08/2025, the officer reported a series of open-market sales of United Therapeutics common stock, including transactions of 400, 2,957, 6,529, 3,295, 3,139, 1,559, 477, 523, 742, 739, 120 and 520 shares, at reported weighted average prices ranging from about $475.08 to $486.71 per share, each executed in multiple trades within specified price ranges.

How many United Therapeutics (UTHR) shares does the officer own after these transactions?

After the reported option exercise and subsequent sales on 12/08/2025, the officer directly owned 8,142 shares of United Therapeutics common stock, as shown in Table I of the filing.

Were the United Therapeutics (UTHR) insider trades made under a Rule 10b5-1 plan?

Yes. The explanation states that the exercise of stock options and subsequent sale of shares on 12/08/2025 were carried out pursuant to a Rule 10b5-1 trading plan that the reporting person entered into on August 5, 2025.

What derivative securities were involved in the United Therapeutics (UTHR) Form 4 filing?

The filing reports a stock option covering 21,000 shares of United Therapeutics common stock with an exercise price of $146.03 per share, exercisable from 03/15/2020 and expiring on 03/15/2027. On 12/08/2025, the officer exercised 21,000 of these options, leaving 3,517 derivative securities beneficially owned afterward.

What is the officer’s relationship to United Therapeutics (UTHR) in this Form 4?

The reporting person is identified as an officer of United Therapeutics Corporation, serving as CFO and Treasurer, and the Form 4 is filed for one reporting person on an individual basis.